Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-10-18

Clinical Trial Update: A Study of LY2140023 in Patients With Schizophrenia [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update for LY2140023 in schizophrenia; study terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • LY2140023

Snippet

Sponsor: Denovo Biopharma LLC | Conditions: Schizophrenia | Phase 3 | Status: TERMINATED | Results posted: 2022-10-18